Serveur d'exploration Tocilizumab - Analysis (France)

Index « Auteurs » - entrée « Clare Proudfoot »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Clare Pain < Clare Proudfoot < Clare W J. Proudfoot  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 3.
Ident.Authors (with country if any)Title
000097 (2019) Ernest Choy [Royaume-Uni] ; Nick Freemantle [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Laurence Pollissard [France] ; Andreas Kuznik [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Erin Mangan [États-Unis] ; Paulo Carita [France] ; Thi-Minh-Thao Huynh [France]Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
000103 (2019) Ernest Choy [Royaume-Uni] ; Nick Freemantle [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Laurence Pollissard [France] ; Andreas Kuznik [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Erin Mangan [États-Unis] ; Paulo Carita [France] ; Thi-Minh-Thao Huynh [France]Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses
000110 (2019) Noemi Muszbek [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Marie Fournier [France] ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Zsofia Kiss [Royaume-Uni] ; Peter Gal [Hongrie] ; Kaleb Michaud [États-Unis]Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs

List of associated KwdEn.i

Nombre de
documents
Descripteur
3Arthritis, Rheumatoid (drug therapy)
3Humans
2Antibodies, Monoclonal, Humanized (therapeutic use)
2Antirheumatic Agents (therapeutic use)
1Adalimumab (economics)
1Adalimumab (therapeutic use)
1Adolescent
1Adult
1Aged
1Antibodies, Monoclonal (economics)
1Antibodies, Monoclonal (therapeutic use)
1Antibodies, Monoclonal, Humanized (administration & dosage)
1Antibodies, Monoclonal, Humanized (adverse effects)
1Antibodies, Monoclonal, Humanized (economics)
1Antibodies, Monoclonal, Humanized (pharmacology)
1Antirheumatic Agents (administration & dosage)
1Antirheumatic Agents (adverse effects)
1Antirheumatic Agents (economics)
1Antirheumatic Agents (pharmacology)
1Arthritis, Rheumatoid (economics)
1Arthritis, Rheumatoid (etiology)
1Arthritis, Rheumatoid (metabolism)
1Certolizumab Pegol (economics)
1Certolizumab Pegol (therapeutic use)
1Cost-Benefit Analysis
1Drug Therapy, Combination
1Etanercept (economics)
1Etanercept (therapeutic use)
1Female
1Male
1Medication Therapy Management
1Methotrexate (economics)
1Methotrexate (therapeutic use)
1Middle Aged
1Network Meta-Analysis
1Piperidines (therapeutic use)
1Pyrimidines (therapeutic use)
1Pyrroles (therapeutic use)
1Treatment Outcome
1Tumor Necrosis Factor-alpha (antagonists & inhibitors)
1Young Adult

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Clare Proudfoot" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Clare Proudfoot" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Clare Proudfoot
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021